Compare BGIN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGIN | CERS |
|---|---|---|
| Founded | 2019 | 1991 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | EDP Services |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.9M | 276.0M |
| IPO Year | 2025 | 1997 |
| Metric | BGIN | CERS |
|---|---|---|
| Price | $3.34 | $2.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 32.7K | ★ 1.6M |
| Earning Date | 02-22-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $205,457,324.00 | $199,191,000.00 |
| Revenue This Year | N/A | $25.31 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.03 |
| 52 Week Low | $2.38 | $1.12 |
| 52 Week High | $6.50 | $2.96 |
| Indicator | BGIN | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 58.68 |
| Support Level | $3.20 | $2.44 |
| Resistance Level | $3.52 | $2.74 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 56.34 | 51.76 |
BGIN Blockchain Ltd is operating through its subsidiaries and is engaged in digital asset technology company based in Singapore, Hong Kong and the U.S. with proprietary cryptocurrency-mining technologies and a strategic focus on alternative cryptocurrencies. It design and sell mining machines equipped with proprietary 8nm or 12nm ASIC chips under different series dedicated to the mining of KAS coins, ALPH coins, and RXD coins. The Company operated in two reportable segments, which were the cryptocurrency mining and the sale of mining machines Key revenue is generated from Sale of mining machines. Geographically, It derives key revenue from Hong Kong, China and Vietnam, United States, Singapore, etc.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.